{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:23:26Z","timestamp":1790357006854,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T00:00:00Z","timestamp":1446422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jhep.2015.10.005","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T13:21:24Z","timestamp":1445779284000},"page":"301-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir\/paritaprevir\/r and dasabuvir for 12 weeks"],"prefix":"10.1016","volume":"64","author":[{"given":"Jordan J.","family":"Feld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Horsmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy","family":"Elkhashab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Reindollar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Howieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshanth R.","family":"Polepally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pangerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy S.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Poordad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.10.005_b0005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.10.005_b0010","unstructured":"World Health Organization. Global Alert and Response (GAR) \u2013 Hepatitis C, <http:\/\/www.who.int\/csr\/disease\/hepatitis\/whocdscsrlyo2003\/en\/index2.html> 2015 [accessed 22.06.15]."},{"key":"10.1016\/j.jhep.2015.10.005_b0015","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","article-title":"Hepatitis C","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.10.005_b0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.10.005_b0025","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"AASLD\/IDSA HCV guidance panel hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.10.005_b0030","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis","volume":"147","author":"H\u00e9zode","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.10.005_b0035","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.10.005_b0040","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.10.005_b0045","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.10.005_b0050","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.10.005_b0055","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.10.005_b0060","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.10.005_b0065","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.10.005_b0070","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1473-3099(15)70050-2","article-title":"Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)","volume":"15","author":"Bourliere","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2015.10.005_b0075","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2015.3868","article-title":"Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis","volume":"313","author":"Muir","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2015.10.005_b0080","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.10.005_b0085","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/apt.12625","article-title":"The impact of hepatitis C burden: an evidence-based approach","volume":"39","author":"Younossi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.10.005_b0090","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1517\/14656566.2014.889116","article-title":"New antiviral agents for the treatment of hepatitis C: ABT-450","volume":"15","author":"Carrion","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jhep.2015.10.005_b0095","series-title":"VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets)","year":"2015"},{"key":"10.1016\/j.jhep.2015.10.005_b0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"Andreone","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.10.005_b0105","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r\u2013ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.10.005_b0110","doi-asserted-by":"crossref","unstructured":"Maieron A, Puoti M, Enejosa JV, Ben Ari Z, Norkrans G, Romero-Gomez M, et al. SVR12 of 99% achieved with a ribavirin-free regimen of ABT-450\/r\/ombitasvir and dasabuvir in HCV genotype 1b-infected patients. In: Presented at The 79th Annual Scientific Meeting of the American College of Gastroenterology, Philadelphia, PA, USA, October 20, 2014.","DOI":"10.14309\/00000434-201410002-00440"},{"key":"10.1016\/j.jhep.2015.10.005_b0115","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2015.10.005_b0120","unstructured":"Hill A, Saleem J. Effects of sustained virological response on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with hepatitis C infection. In: Presented at American Association for the Study of Liver Diseases, Boston, MA, November 10, 2014."},{"key":"10.1016\/j.jhep.2015.10.005_b0125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22694","article-title":"Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients","volume":"49","author":"George","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.10.005_b0130","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/cit103","article-title":"Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV\/hepatitis C virus-coinfected patients with compensated cirrhosis","volume":"56","author":"Mira","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.10.005_b0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.27826","article-title":"Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis","volume":"62","author":"Reddy","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.10.005_b0140","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/S0168-8278(15)30158-6","article-title":"A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2","volume":"62","author":"Lawitz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.10.005_b0145","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"Sulkowski","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.10.005_b0150","unstructured":"Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. In: Presented at European Association for the Study of the Liver, 49th International Liver Congress Vienna, Austria, April 22\u201326, 2015."},{"issue":"11","key":"10.1016\/j.jhep.2015.10.005_b0155","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1111\/liv.12931","article-title":"Ombitasvir\/paritaprevir\/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopenia and hypoalbuminemia","volume":"35","author":"Forns","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.10.005_b0160","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1053\/j.gastro.2015.07.001","article-title":"Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus with and without cirrhosis","volume":"149","author":"Lawitz","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.10.005_b0165","doi-asserted-by":"crossref","first-page":"S644","DOI":"10.1016\/S0168-8278(15)31023-0","article-title":"Pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection in phase 3 studies","volume":"62","author":"Mensing","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.10.005_b0170","series-title":"REBETOL (ribavirin USP) capsules, for oral use","year":"2015"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815006765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815006765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T07:05:40Z","timestamp":1599721540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815006765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0168827815006765"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.10.005","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir\/paritaprevir\/r and dasabuvir for 12weeks","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}